Live Breaking News & Updates on Worsening Diarrhea Complicated

Stay updated with breaking news from Worsening diarrhea complicated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021

RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Herbertl Dupont , Amber Fennell , Bryan Gibbs , Redhill Biopharma , Adi Frish , June Almenoff , Centers For Disease , Cosmo Pharmaceuticals Investor Presentation , Redhill Biopharma Inc , Redhill Biopharma Ltd , Company Annual Report On Form , Exchange Commission , Company Expanded Access Program , Development Of Drug , Cosmo Pharmaceutical Multi Matrix Technology , Cosmo Technologies Ltd , Digestive Disease Week , Traveler Diarrhea , Infectious Diseases , Texas Houston School , Professor Herbert , Chief Medical , Disease Control , Worsening Diarrhea Complicated ,

RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021

RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Herbertl Dupont , Amber Fennell , Bryan Gibbs , Redhill Biopharma , Adi Frish , June Almenoff , Centers For Disease , Cosmo Pharmaceuticals Investor Presentation , Redhill Biopharma Inc , Redhill Biopharma Ltd , Company Annual Report On Form , Exchange Commission , Company Expanded Access Program , Development Of Drug , Company Codes , Cosmo Pharmaceutical Multi Matrix Technology , Cosmo Technologies Ltd , Digestive Disease Week , Traveler Diarrhea , Infectious Diseases , Texas Houston School , Professor Herbert , Chief Medical , Disease Control ,

RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D

Share this article
TEL AVIV, Israel and RALEIGH, N.C,, Jan. 11, 2021 /PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today reported that its partner, Cosmo Pharmaceuticals (SIX: COPN) ( Cosmo ), announced that it had successfully completed their Phase 2 Proof-of-Concept (POC) clinical trial of Rifamycin SV-MMX 600mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
As part of an exclusive license agreement between RedHill and Cosmo from October 2019 for the U.S. rights to Aemcolo
® (rifamycin), RedHill maintains certain rights, including a right of first refusal, in relation to Rifamycin SV-MMX 600 mg in the U.S. ....

Dror Ben Asher , Bryan Gibbs , Redhill Biopharma , Adi Frish , Cosmo Pharmaceuticals , Redhill Biopharma Inc , Redhill Biopharma Ltd , Exchange Commission , Company Annual Report On Form , Development Of Drug , Company Expanded Access Program , Cosmo Pharmaceutical Multi Matrix Technology , Corporate Business Development , Prnewswire Redhill Biopharma Ltd , Hill Biopharma , Worsening Diarrhea Complicated , Associated Diarrhea , Private Securities Litigation Reform Act , Expanded Access Program , Annual Report , திறோர் பென் ஆஷர் , பிரையன் கிப்ஸ் , பிரபஞ்சம் மருந்துகள் , பரிமாற்றம் தரகு , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் , வளர்ச்சி ஆஃப் மருந்து ,